BioCentury | Nov 6, 2019
Company News

Allogene sets sights on iPS cell-based allogeneic therapies via Notch partnership

...David Chang told BioCentury. “This is a space we have to have a play in.” Notch Therapeutics Inc....
...for Commercialization of Regenerative Medicine, which incubated Notch. Elizabeth S. Eaton, Staff Writer Allogene Therapeutics Inc. University of Toronto Notch Therapeutics Inc....
Items per page:
1 - 1 of 1
BioCentury | Nov 6, 2019
Company News

Allogene sets sights on iPS cell-based allogeneic therapies via Notch partnership

...David Chang told BioCentury. “This is a space we have to have a play in.” Notch Therapeutics Inc....
...for Commercialization of Regenerative Medicine, which incubated Notch. Elizabeth S. Eaton, Staff Writer Allogene Therapeutics Inc. University of Toronto Notch Therapeutics Inc....
Items per page:
1 - 1 of 1